Clinical Trials Logo

Filter by:
NCT ID: NCT05437068 Not yet recruiting - Malnutrition, Child Clinical Trials

Nutritional Supplementation in Children at Risk of Undernutrition

Start date: November 2022
Phase: N/A
Study type: Interventional

This is a prospective, multicenter, single-arm intervention study. The expected duration of study participation for each participant is approximately 120 days. The current study aims to investigate the effectiveness of an ONS formula in children at risk or with undernutrition in Thailand.

NCT ID: NCT05425524 Recruiting - Leptospirosis Clinical Trials

Leptospirosis Care Bundle Study

Start date: October 1, 2019
Phase: N/A
Study type: Interventional

So in management of Leptospirosis patients There really is no another approach to treatment. The importance of the problem was acknowledged by the researchers. As a result, this study was performed in order to The Leptospirosis Care Bundle has been used, and has been proved that its use can reduce the risk of acute renal failure.

NCT ID: NCT05416697 Not yet recruiting - Malnutrition Clinical Trials

Effectiveness of Cannabinoids on Appetite in Scleroderma

Start date: July 2022
Phase: Phase 3
Study type: Interventional

The cannabinoid has benefits in many aspects but the evidence of the effect of cannabinoids in humans with SSc is limited. We, therefore, would like to investigate the efficacy of cannabinoids on the appetite, sleep efficiency, quality of life, pain, and critical cytokine level in SSc compared with placebo in SSc patients and the adverse events associated with cannabinoids in those patients.

NCT ID: NCT05414747 Not yet recruiting - Retinal Detachment Clinical Trials

Clinical Investigation of the Safety and Effectiveness of the ABV-1701 Ocular Endotamponade (OE)

Start date: June 1, 2022
Phase: N/A
Study type: Interventional

A Prospective Multi-Site Open Label Randomized Controlled Clinical Investigation of the Safety and Effectiveness of the ABV-1701 Ocular Endotamponade (OE)

NCT ID: NCT05410210 Recruiting - Parkinson Disease Clinical Trials

Impact of Pharmaceutical Care on Drug-related Problems in Patients With Parkinson's Disease

Start date: March 11, 2022
Phase: N/A
Study type: Interventional

The aim of this study is to evaluate the impact of pharmaceutical care on the number of drug-related problems, clinical outcomes and quality of life of patients with Parkinson's disease.

NCT ID: NCT05406908 Not yet recruiting - Psoriasis Clinical Trials

Intradermal Tozinameran for Patients With Immune-mediated Dermatologic Diseases

Start date: June 1, 2022
Phase: Phase 4
Study type: Interventional

This is a randomised controlled trial conducted to prove that the immunological performance of intradermal tozinameran (i.e., Pfizer-BioNTech COVID-19 vaccine) is no worse than the standard intramuscular route in patients with immune-mediated dermatologic diseases. The side effects profile and disease activity post-vaccination will also be assessed.

NCT ID: NCT05406583 Not yet recruiting - HIV Clinical Trials

A Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1

Start date: July 2022
Phase: Phase 1
Study type: Interventional

This study will test an anti-HIV drug (ARV) for newborn babies. The study will include a minimum of 36 and up to 108 mothers living with HIV and their newborn babies from Brazil, South Africa, Thailand, and the United States. Infants will be in the study for approximately 16 weeks (four months) after they are born. Mothers will not receive study drug and will exit the study after the Entry visit.

NCT ID: NCT05401695 Completed - Septic Shock Clinical Trials

The Role of Blood Purification by Hemoadsorption as Adjunctive Treatment in Children With Septic Shock

Start date: July 1, 2021
Phase: N/A
Study type: Interventional

Sepsis is a major healthcare problem and leading cause of death in the pediatric population. Despite advances in supportive care of critically ill patients, sepsis remains an important cause of death worldwide in children. Overall, sepsis incidence peaked in early childhood. There were an estimated 20.3 million incident sepsis cases worldwide among children younger than 5 years. The Surviving Sepsis Campaign (SSC), which standardized the evidence-base approach to management of septic shock and other sepsis-associated organ dysfunction in children, was recently updated. Nevertheless, mortality and costs are still high. Sepsis is characterized by a complex systemic inflammatory response to a microbial pathogen. A dysregulated host response to infection may result in life-threatening multi-organ dysfunction. Endotoxin, which is found in the outer membrane of Gram-negative bacteria, plays an important role in the pathogenesis of septic shock by producing proinflammatory cytokines. High levels of endotoxin and proinflammatory cytokines are associated with a high mortality rate. Treatment strategies in sepsis and septic shock include early and adequate fluid resuscitation, vasopressors and inotropic support when indicated, early use of broad-spectrum antibiotics with source control, with close monitoring and organ support, if indicated. Other therapies such as immune-modulation and blood purification have been tried to improve outcomes in patients with sepsis and septic shock. Immunomodulation and blood purification techniques aim at restoring the balance of the immune response to infection, by removing the triggers for the response and the cytokines produced and thereby achieve immune homeostasis. Removing endotoxin and inflammatory cytokines would be an effective adjunctive approach in the management of severe sepsis. Direct hemoadsorption (HA) is an extracorporeal technique utilized for blood purification. It involves the passage of blood through an adsorption cartridge, where solutes are removed by direct binding to the sorbent material. Over the years, new adsorption cartridge, with improved characteristics have been developed. Resin-directed hemoadsorption is associated with improved oxygenation, hemodynamic status and cardiac function. However, most studies include only adults, and little information is available regarding the clinical experience and efficacy of blood purification for pediatric septic shock. This pilot study aimed to evaluate the overall clinical outcomes among children who received direct hemoadsorption as an adjunctive treatment for refractory septic shock with high severity scores, compared with outcomes among children admitted to the PICU who received standard treatment.

NCT ID: NCT05397054 Recruiting - Hypertension Clinical Trials

Intervention for Monitoring of Salt Intake in Hypertensive Patients

Start date: January 10, 2022
Phase: N/A
Study type: Interventional

Sodium is an essential nutrient for humans, but excessive sodium consumption is causally associated with high blood pressure and increase risk of cardiovascular diseases. Dietary sodium consumption of greater than the recommended daily amount of 5 grams of salt or 2,000 mg of sodium is a major risk factor for CVD-related mortality. From recent national survey, Thai people had consumed more than 9.1 g of salt per day, which was nearly two times above WHO reference level. Dietary salt reduction was unsuccessful because of lacking awareness, and the higher threshold to detect salt taste in chronic high salt ingestion. To create awareness in the community, we should be educated, managed the environmental for salt reduction, and used salt meter to detect sodium content in daily food. This study aimed to compare the efficacy of intervention; education, reformulation, environmental change and used salt meter compared with standard treatment alone in terms of salt intake reduction and blood pressure.

NCT ID: NCT05389540 Not yet recruiting - Infections Clinical Trials

Rural South and Southeast Asia Household Health Survey

SEACTN-HHS
Start date: June 2022
Phase:
Study type: Observational

A cross-sectional household survey with two-stage cluster-randomized sampling. This cross-sectional household survey design to recruit a random sample of households that is representative for each of the study sites. From the selected households, all consenting, household members will be included in the study. This study is funded by the UK Wellcome Trust. The grant reference number is 215604/Z/19/Z